IP Library Granted Patent US 9,439,877
Granted Patent B2
US 9,439,877 · App. 14/795,056 · Granted Sep 13, 2016

Small molecule inhibitors of Dusp6 and uses therefor

Inventors: Billy W. Day (Pittsburgh, PA); Waikok Michael Tsang (Pittsburgh, PA); Vasiliy N. Korotchenko (Rockville, MD)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
A61K31/135C07C211/42C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,877
App. No.
14/795,056
Granted
Sep 13, 2016
Kind
B2
Abstract

Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses.

Claims (22)

1. A method of repairing a cardiac muscle defect in a patient, comprising contacting a cardiac cell of the patient with a compound having the formula:

in which R1 represents one or more independently of H, halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN; R2 is a secondary or tertiary amine group; R3 is one or more independently of halo, C 1-3 alkyl, C 1-3 alkoxyl or —CN; and R4 is ═O or —OH, or a pharmaceutically acceptable salt thereof, in an amount effective to increase FGF secretion by the cell.

2. The method of claim 1 , wherein the cardiac cell is a cardiomyocyte.

3. The method of claim 2 , wherein the method further comprises obtaining one or more cardiomyocytes cells from a patient and contacting the one or more cardiomyocytes in vitro with the compound to expand the cardiomyocytes.

4. The method of claim 1 , wherein the defect is a congenital defect.

5. The method of claim 1 , wherein the defect is a wound.

6. The method of claim 1 , wherein R3 is halo.

7. The method of claim 6 , where R3 is Br.

8. The method of claim 1 , wherein R2 is a C 4-10 cycloalkylamine.

9. The method of claim 1 , wherein R2 is one of cyclopentylamine and cycloheptylamine.

10. The method of claim 1 , wherein R1 is H, R2 is one of cyclopentylamine, cyclohexylamine, and cycloheptylamine, and R3 is Br.

11. The method of claim 10 , wherein R2 is cyclohexylamine.

12. The method of claim 1 , wherein the compound consists essentially of a (−) enantiomer.

13. The method of claim 1 , wherein the compound has the formula:

14. The method of claim 1 , wherein R4 is ═O.

15. The method of claim 14 , wherein R2 is one of 4-t-Boc-cyclohexylamine, thiamorpholine, piperazine, methyl piperazine, acetyl piperazine, cyclopentylamine, cycloheptylamine and di-C 1-4 -alkylamine.

16. The method of claim 1 , wherein R4 is —OH.

17. The method of claim 1 , wherein R1 is 3,4-di-halo.

18. The method of claim 1 , wherein R1 is 3,4-dichloro.

19. The method of claim 1 , wherein the compound has the structure:

20. A method of repairing a damaged or deficient cardiac muscle in a patient, comprising contacting a cardiomyocyte of the patient with a compound having the formula:

or a pharmaceutically acceptable salt thereof, in an amount effective to increase levels of phosphorylated ERK or to decrease levels of de-phoshoprylated ERK in the cardiomyocyte.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2015
From: DAY, BILLY W.; TSANG, WAIKOK MICHAEL; KOROTCHENKO, VASILIY N.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 036055/0179 →
Continuity (3)
Continuation 13256584
Provisional Application 61210643 · Mar 20, 2009
Related Publication 20160113889A1 · Apr 28, 2016